BOTHELL, Wash., Dec. 14 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (the “Company”) has moved from its former facilities in Kirkland, Washington and combined all of its corporate and administrative, R&D, imaging, manufacturing and support operations into its now state-of-the-art research facilities and new corporate headquarters in the Seattle-area city of Bothell, Washington.
The Company took on the 26,500 square foot facility, located in the Canyon Park biotechnology complex, in May 2007 and has completely renovated the entire site in order to accommodate CellCyte’s anticipated needs for years to come.
This facility now houses four full-scale research laboratories, three tissue culture labs for the growth and expansion of stem cells, a specialized “hot lab” for the radio-active labeling of cells, two laboratories dedicated to device manufacturing, cell expansion and stem cell purification, a dedicated nuclear imaging suite incorporating the SPECT/CT camera, a full animal research vivarium facility, support services and the corporate offices of CellCyte Genetics.
CellCyte Genetics will now use this facility as a staging point for worldwide operations and as the main research facility for carrying out preclinical studies in support of its planned clinical trials, and the development of its broad pipeline of intellectual property.
As part of its scaling-up process, the Company has added Kim J. Kimbell, SPHR, CCP, as the new Head of Human Resources for CellCyte Genetics Corp.
Kim Kimbell was formerly Director of Human Resources for MDS Pharma (Formerly Skeletech, Inc.) a Seattle-area Clinical Research Organization, which she helped grow from start-up to the company’s successful acquisition. She was Human Resources Manager for Zymogenetics, Inc., another growing Seattle-based biotech firm, where she was responsible for new hires and staff requirements for that company’s rapidly growing employee roster.
Ms. Kimbell joins CellCyte in order to effectively manage a major increase in staffing needs and to attract a high caliber of key personnel as the Company occupies its new facility and approaches toxicology studies and a planned clinical trial.
“I have to hand it to our excellent team,” states Gary Reys, Chairman and CEO. “They have done an outstanding job in putting these new facilities in place in a relatively short period of time. We have been able to create a showcase for biotechnology research and product development at about the half the cost of many peer biotech companies.”
“With our research teams, support staff and management now in one state- of-the-art facility, we can focus all efforts on completing preclinical investigations on our lead indication; delivering adult stem cells to heal the heart. That’s what this is all about.”
About CellCyte Genetics
CellCyte Genetics, a Washington State company, is an emerging biotechnology company engaged in the principle business of the discovery, development and commercialization of breakthrough stem cell enabling therapeutic products.
http://www.cellcyte.com
Safe Harbor Statement
THIS NEWS RELEASE CONTAINS “FORWARD-LOOKING STATEMENTS”, AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS “ESTIMATE,” “ANTICIPATE,” “BELIEVE,” “PLAN” OR “EXPECT” OR SIMILAR STATEMENTS ARE FORWARD- LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH THE CLOSING OF THE SHARE EXCHANGE AGREEMENT AND THE DEVELOPMENT AND FUNDING OF THE COMPANY CONSEQUENT THEREON, AS WELL AS THE RISKS SHOWN IN THE COMPANY’S MOST RECENT ANNUAL REPORT ON FORM 10-KSB AND ON FORM 10-QSB AND FROM TIME-TO-TIME IN OTHER PUBLICLY AVAILABLE INFORMATION REGARDING THE COMPANY. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE COMPANIES, FUTURE CAPITAL REQUIREMENTS AND THE COMPANY’S ABILITY AND LEVEL OF SUPPORT FOR ITS RESEARCH AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY’S DEVELOPMENT EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS.
THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY’S PERIODIC REPORTS FILED FROM TIME-TO- TIME WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION. THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT OF THE COMPANY WHO TAKE FULL RESPONSIBILITY FOR ITS CONTENTS. EACH OF THE NASD, THE SEC AND THE OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE CONTENTS OF THIS NEWS RELEASE. THIS NEWS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
CONTACT: CellCyte Genetics Corporation, North America, Investor Relations,
1-877-688-5050, or Europe, Investor Relations, (+49) 69.7593.8451
